DHSC publishes second list of February price concessions

The UK government have been accused of putting off investors in drug manufacturing over the “unsustainable levy” companies are having to pay the NHS.

Industry leaders have warned that the government’s growth plan will not succeed unless ministers commit to fixing a scheme which now requires companies to make record payments up to a quarter to a third (23.5 per cent-35.6 per cent) of a company’s revenue from sales of branded medicines to the NHS.